Physician profile
Mark D Herron
NPI 1942271812
$12,325.23
in general payments reported to CMS, 2019-2025
23 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $745 · 2021: $1,078 · 2022: $1,884 · 2023: $2,641 · 2024: $2,511 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,218 · Education: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,218.09 |
| Education | $529.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,782.15 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,752.44 | 2019-2025 | |
| Janssen Biotech, INC. | $1,568.92 | 2019-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $1,228.31 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,176.08 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $671.42 | 2022-2025 | Sotyktu |
| Amgen INC. | $597.57 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $374.85 | 2019-2025 | |
| Lilly USA, LLC | $311.58 | 2020-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $304.94 | 2022-2025 | Nemluvio, Oracea, Aklief |
| Pfizer INC. | $299.27 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $259.97 | 2022-2025 | |
| Dermavant Sciences, INC. | $214.33 | 2023-2024 | Vtama |
| Ucb, INC. | $145.35 | 2019-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $127.82 | 2024-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $118.59 | 2019-2020 | |
| Leo Pharma INC. | $108.45 | 2022-2024 | Adbry |
| Janssen Scientific Affairs, LLC | $90.66 | 2020 | |
| Incyte Corporation | $87.11 | 2022-2023 | Opzelura |
| Organon LLC | $39.70 | 2025 | Vtama |
| Celgene Corporation | $31.16 | 2019 | |
| Epi Health, LLC | $19.02 | 2022 | |
| Medtronic, INC. | $15.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Herron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.